Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
暂无分享,去创建一个
P. Mclaughlin | F. Cabanillas | F. Cabanillas | A. Younes | R. Champlin | S. Giralt | F. Hagemeister | F. Hagemeister | J. Gajewski | P. Anderlini | M. Lee | I. Khouri | M. Donato | R. Champlin | C. Ippoliti | M. Korbling | R. Saliba | J. Gajewski | G. Okoroji | S. Giralt | Ming-Sheng Lee
[1] P. Bierman. Allogeneic bone marrow transplantation for lymphoma. , 2000, Blood reviews.
[2] N. Ueno,et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Kornblau,et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. , 1999, Current opinion in oncology.
[4] J. Armitage,et al. Allogeneic bone marrow transplantation for low-grade lymphoma. , 1998, Blood.
[5] J. Ferrara,et al. Cytokine dysregulation and acute graft-versus-host disease. , 1992, Blood.
[6] F. Appelbaum,et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Kantarjian,et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] H. Donis-Keller,et al. USE OF DNA RESTRICTION FRAGMENT LENGTH POLYMORPHISMS TO DOCUMENT MARROW ENGRAFTMENT AND MIXED HEMATOPOIETIC CHIMERISM FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.
[9] L. Gordon,et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] K. Cleary,et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect , 1997, Bone Marrow Transplantation.
[11] H. Kantarjian,et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[13] M. Grever,et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[15] W. Velasquez,et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Pileri,et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion , 2000 .
[17] A. Norton,et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] W. Plunkett,et al. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. , 1993, Leukemia & lymphoma.
[19] B. Andersson,et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] P. Biron,et al. High dose chemotherapy with autologous marrow transplantation in follicular lymphomas. , 1992, Leukemia & lymphoma.
[21] N. Ueno,et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. , 1999, Blood.
[22] H. Kantarjian,et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. , 1996, The American journal of medicine.
[23] M. Andreeff,et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. , 1996, Bone marrow transplantation.
[24] A. López-Guillermo,et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. , 1999, Blood.
[25] Treatment approaches to the low-grade lymphomas. , 1994 .
[26] L. Verdonck,et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. , 1997, Blood.
[27] D. Weisenburger,et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. , 1989, Blood.
[28] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.
[29] J. Armitage,et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] N. Ueno,et al. Allogeneic hematopoietic transplantation for indolent lymphomas: improved outcome with non-myeloablative versus high dose chemotherapy (HDCT) regimens , 2000 .